^
    17h
    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov)
    P3, N=315, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2027 --> Sep 2028
    Trial completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HR positive • HER-2 negative • ESR1 mutation • HR positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation • HER-2 negative + HR positive + ESR1 mutation
    |
    Guardant360® CDx
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)
    18h
    BC-BIO: Predictive Clinical and Biological Parameters in Breast Cancer (clinicaltrials.gov)
    P=N/A, N=749, Terminated, Institut Paoli-Calmettes | Trial completion date: Dec 2029 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Jan 2026; strategical decision
    Trial completion date • Trial termination • Trial primary completion date
    18h
    Effectiveness of a Visual Biofeedback Program Versus Conventional Physiotherapy on Shoulder Mobility, Strength, and Function in Women After Breast Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, University of Extremadura
    New trial
    19h
    PIKHER2: Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=24, Terminated, Institut Paoli-Calmettes | N=106 --> 24 | Suspended --> Terminated; Drug development withdrawn
    Enrollment change • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • lapatinib • buparlisib (AN2025)
    20h
    Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease (clinicaltrials.gov)
    P3, N=242, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Mar 2028 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    20h
    FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (clinicaltrials.gov)
    P2, N=99, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative • PGR positive
    20h
    OFFLINE-PET-PR: Verification of Range Accuracy and Correlation With Clinical Toxicity Using Offline PET/CT for Hypofractionated Proton Radiotherapy in Breast Cancer (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Ruijin Hospital
    New trial
    20h
    Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, Regor Pharmaceuticals Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    20h
    Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer (clinicaltrials.gov)
    P=N/A, N=2200, Active, not recruiting, Spotlight Medical
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    20h
    Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection (clinicaltrials.gov)
    P3, N=534, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Nov 2026 --> Nov 2025
    Trial primary completion date
    21h
    PERTUREAL: Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Société Algérienne de Formation et Recherche en Oncologie
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Perjeta (pertuzumab)
    21h
    Digital Mind-Body Therapy for Neoadjuvant Breast Cancer (clinicaltrials.gov)
    P=N/A, N=66, Recruiting, Fudan University
    New trial